Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,098 | 47 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $206.78 | 13 | $0 (2023) |
| Blueprint Medicines Corporation | $128.89 | 1 | $0 (2021) |
| Celgene Corporation | $127.59 | 2 | $0 (2022) |
| Janssen Biotech, Inc. | $103.87 | 6 | $0 (2022) |
| Lilly USA, LLC | $102.06 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $71.82 | 4 | $0 (2022) |
| Incyte Corporation | $59.69 | 3 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $59.37 | 3 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $54.91 | 3 | $0 (2022) |
| PFIZER INC. | $45.57 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $17.10 | 1 | Novartis Pharmaceuticals Corporation ($17.10) |
| 2022 | $391.20 | 18 | Novartis Pharmaceuticals Corporation ($103.32) |
| 2021 | $690.03 | 28 | Blueprint Medicines Corporation ($128.89) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/15/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Oncology | ||||||
| 09/13/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: Oncology | ||||||
| 07/05/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Oncology | ||||||
| 05/11/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: ONCOLOGY | ||||||
| 05/04/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Oncology | ||||||
| 05/03/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: ONCOLOGY | ||||||
| 04/27/2022 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: ONCOLOGY | ||||||
| 04/05/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Oncology | ||||||
| 03/23/2022 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 03/23/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2022 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: Oncology | ||||||
| 01/27/2022 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 01/18/2022 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $102.06 | General |
| 01/18/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Oncology | ||||||
| 01/12/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: Oncology | ||||||
| 01/04/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.79 | General |
| Category: Hematology | ||||||
| 12/22/2021 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | Cash or cash equivalent | $20.33 | General |
| Category: Oncology | ||||||
| 10/28/2021 | Blueprint Medicines Corporation | GAVRETO (Drug) | Food and Beverage | In-kind items and services | $128.89 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/20/2021 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $108.80 | General |
| 10/13/2021 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $11.81 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/25/2021 | Incyte Corporation | PEMAZYRE (Drug), JAKAFI | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 05/19/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 5 | 124 | 167 | $43,678 | $15,424 |
| 2021 | 1 | 28 | 28 | $11,536 | $4,948 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 43 | $17,716 | $7,262 | 41.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 38 | $10,032 | $3,361 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 12 | 26 | $6,630 | $1,919 | 28.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 30 | $5,370 | $1,852 | 34.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 30 | $3,930 | $1,030 | 26.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 28 | 28 | $11,536 | $4,948 | 42.9% |
About Dr. Enrique Davila, MD
Dr. Enrique Davila, MD is a Hematology & Oncology healthcare provider based in Aventura, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1750378709.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Enrique Davila, MD has received a total of $1,098 in payments from pharmaceutical and medical device companies, with $17.10 received in 2023. These payments were reported across 47 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,098).
As a Medicare-enrolled provider, Davila has provided services to 152 Medicare beneficiaries, totaling 195 services with total Medicare billing of $20,372. Data is available for 2 years (2021–2022), covering 6 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Aventura, FL
- Active Since 10/04/2005
- Last Updated 09/25/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750378709
Products in Payments
- GAVRETO (Drug) $128.89
- KISQALI (Drug) $111.32
- DARZALEX (Biological) $73.53
- ZEJULA (Drug) $71.82
- KEYTRUDA (Biological) $59.37
- LUTATHERA (Drug) $57.54
- BOSULIF (Drug) $45.57
- JAKAFI (Drug) $39.69
- IMFINZI (Biological) $35.91
- BRUKINSA (Drug) $32.12
- Optune (Device) $22.89
- PROMACTA (Drug) $21.89
- Cabometyx (Drug) $20.33
- PEMAZYRE (Drug) $20.00
- ZEPZELCA (Drug) $19.20
- LYNPARZA (Drug) $19.00
- REBLOZYL (Biological) $18.79
- Lenvima (Drug) $17.74
- IMBRUVICA (Drug) $16.47
- TABRECTA (Drug) $16.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Aventura
Alejandra Del Toro, M.d, M.D
Hematology & Oncology — Payments: $18,346
Miss. Jennifer Cudris Maldonado, M.d, M.D
Hematology & Oncology — Payments: $12,626
Gelenis Domingo, M.d, M.D
Hematology & Oncology — Payments: $5,908
Marc Saltzman, M.d, M.D
Hematology & Oncology — Payments: $2,747
Robert Hirsch, Md, MD
Hematology & Oncology — Payments: $985.48
Dr. Jonathan Leslie, D.o, D.O
Hematology & Oncology — Payments: $25.31